dl) with
RxFiles.ca Trial Summary. Sept 2010. ACCORD Lipid & BP Trial Overview. Cardiovascular (CV) Risk in Type 2 Diabetes Mellitus (T2DM): Treatment Strategies. ? ACCORD 1 evaluated drug intervention & aggressive pursuit of targets to v CV risk in T2DM (~10yr history of T2DM) & CV disease or high CV risk. ? 3 Trials:
22 Apr 2011 The ACCORD Lipid trial tested the hypothesis that treatment of patients with type 2 diabetes with fenofibrate to increase plasma HDL cholesterol levels and reduce plasma TG concentrations, on the background of simvastatin therapy, would result in additional cardiovascular benefit compared with
The ACCORD LIPID Trial. Nicola Abate, M.D., and Manisha Chandalia, M.D.. Cardiovascular disease (CVD) is the main cause of morbidity and mortality in patient with type 2 diabetes mellitus (T2DM).1 Providing a therapeutic regimen that ef- fectively reduces risk for developing CVD in T2DM is a major challenge for
29 Apr 2010 sure or plasma lipids on cardiovascular outcomes in 10,251 patients with type 2 diabetes who were at high risk for cardiovascular disease. Here we present the findings of the ACCORD lipid trial. (ACCORD Lipid). Although statins are efficacious in patients with type 2 diabetes, rates of cardiovascular events.
14 Mar 2010 randomly assigned to either intensive or standard glycemic control (the ACCORD glycemia trial). In addition, 5518 of the ACCORD participants were also randomly assigned (in a 2-by-2 factorial de- sign) to either simvastatin plus fenofibrate or simvastatin plus placebo (the ACCORD lipid trial), and the
12 Jun 2008 Diabetes (ACCORD) trial was specifically de- signed to determine . the lipid trial, assignment to the intensive blood- pressure . and lipids. For the primary outcome, there was some evi- dence of heterogeneity among prespecified sub- groups, which suggested that patients in the intensive-therapy group
Edward Lipkin, MD, PhD,j and Jerome L. Fleg, MD,k for the ACCORD Study Group†. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial aims to test whether a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) plus a fibrate is more efficacious in reducing cardiovascular events than a
12 Aug 2010 correspondence. Combination Lipid Therapy in Type 2 Diabetes. To the Editor: In the Action to Control Car diovascular Risk in Diabetes (ACCORD) trial. (ClinicalTrials.gov number, NCT00000620) report ed on by Ginsberg et al. (April 29 issue),1 the use of fenofibrate in patients with type 2 diabetes mellitus
The ACCORD (Action to Control. Cardiovascular Risk in Diabetes). Lipid Trial. What we learn from subgroup analyses. HENRY N. GINSBERG, MD. Atherosclerotic cardiovascular dis- ease is increased severalfold in most patients with type 2 diabetes, particularly patients who are older and have other risk factors (1,2).

Annons

The photo has no tags

February 2018